RxDoctor Payments Data

Shannon Martin

Family · Glen Burnie, MDNPI 1417322926

Payments from drug & device makers

$4,069in general payments, 2019–2025

Across 182 payments — averaging $22.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • USWM, LLC$755
  • Novo Nordisk$378
  • Indivior Inc.$333
  • Teva Pharmaceuticals USA, Inc.$312
  • Otsuka America Pharmaceutical, Inc.$302
  • Gilead$285
  • plus $2K from 21 others

What the payments were for

  • Speaking & faculty fees$3308%
  • Food & beverage$3,64990%
  • Education$902%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,069 in reported general payments places this provider in the 90th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$47,104
Medicare patients
45
Services billed
664

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SuboxoneBuprenorphine Hcl/Naloxone Hcl72$52,451
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl164$25,856
OzempicSemaglutide20$23,072
Xtampza ErOxycodone Myristate11$11,721
OxycontinOxycodone Hcl18$7,821
Oxycodone Hcl41$784
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen21$718
Gabapentin15$512
Baclofen17$422
Morphine Sulfate ErMorphine Sulfate20$405
Albuterol Sulfate HfaAlbuterol Sulfate13$379
Atorvastatin Calcium22$314
Levothyroxine Sodium21$168
Trazodone Hcl11$113
Hydroxyzine Pamoate11$104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Indivior Inc.Suboxone$333$52,45172 claims
Novo NordiskOzempic$378$23,07220 claims
Collegium Pharmaceutical, Inc.Xtampza Er$56$11,72111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,843 family providers in Maryland.

Other family in Glen Burnie

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →